Dr Achim Werner awarded the Ubiquigent Young Scientist Prize at the EMBO-CONICET meeting on 'Ubiquitin and ubiquitin-like proteins: at the crossroads from chromatin to protein"
Dundee, UK, 24th October 2014 - Ubiquigent Ltd. is delighted to announce that Dr Achim Werner was awarded the Ub iquigent Young Scientist Prize at the European Molecular Biology Organisation (EMBO)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) meeting on ‘Ubiquitin and ubiquitin-like proteins: At the crossroads from chromatin to protein' held in Buenos Aires, Argentina in October 2014. Dr Werner is a post-doctoral researcher in Professor Michael Rape's lab at the University of California, Berkeley, USA.
Dr Werner was selected to receive the award by the prize-giving committee for his poster entitled ‘Cell fate determination by ubiquitin-dependent regulation of ribosome function.'
On receiving his prize Dr Werner commented; “It is a great honour to receive this award, especially in light of the wide variety of topics and the overall high quality of research presented at this meeting. The special programme and setting of this conference allowed me to discuss my project with a lot of young and enthusiastic researchers and with prominent scientists in the ubiquitin and chromatin fields. I am deeply thankful to the committee for selecting my research, the organizers for a fantastic meeting with many inspiring talks and discussions, and last but not least Ubiquigent for sponsoring this award that honours and motivates young scientists.”
Ubiquigent's Managing Director Dr Jason Brown added; “Ubiquigent was delighted to continue our sponsorship of a Young Scientist Prize - our second of 2014 - at a leading ubiquitin meeting, this time in collaboration with EMBO and CONICET. We would like to congratulate Dr Werner on being selected by the prize committee. We offer our best wishes to Dr Werner in his future scientific career.”
Ubiquigent Limited (www.ubiquigent.com) is a specialist supplier of high quality reagents, kits and drug discovery assay development and compound profiling services to the commercial and academic life science research community. Ubiquigent's focus is the ubiquitin signalling system and the company has established its scientific and business credentials both with pharmaceutical and biotechnology companies pursuing ubiquitin system-focused drug discovery as well academic researchers undertaking fundamental scientific discovery.
For Ubiquigent contact details click here.